Labcorp (LH) announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions.
To improve patient access to testing, Labcorp announced: availability of new NGS panels for myeloid, lymphoid and pan-heme indications; the launch of a Rapid AML Panel, enhancing test menu for acute myeloid leukemia; expansion of capabilities to OmniSeq INSIGHT: pan-solid tumor profiling test will soon include homologous recombination deficiency testing. The additions also include: expanded FDA-approved companion diagnostics, and enabling digital pathology advancements for anatomic pathology.
Labcorp will now offer Labcorp Plasma Focus, a solid tumor liquid biopsy test, through its Geneva, Switzerland and Shanghai, China sites. The company has launched an enhanced digital pathology platform across its global central labs.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.